# Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

> **NCT04275245** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tang-Du Hospital** · enrollment: 17 (actual)

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)

## Interventions

- **DRUG:** Meplazumab for Injection

## Key facts

- **NCT ID:** NCT04275245
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-03
- **Primary completion:** 2020-03-09
- **Final completion:** 2020-03-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04275245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04275245, "Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04275245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*